Health Care Without Harm aims to transform global healthcare to minimize its environmental impact and promote sustainability. Lorna Rothery spoke to the team about the effects of pharmaceutical pollution and the necessity for the industry to adopt greener practices.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.
Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.
Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.
Dr Frank Wuest, Professor at Department of Oncology - University of Alberta, sheds light on the imaging biomarkers and the Alberta Radiopharmaceutical Collaboration in this special oncology focus.
Here, experts Stephan Pleschka, Oliver Planz and Stephan Ludwig walk us through the constant threat of influenza virus outbreaks and the benefit of enduring research in antiviral drug development.
